Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
Date:6/5/2008

NEW YORK, June 5 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. (AAH: ASX). The full 56-page report can be found at http://www.crystalra.com .

Arana Therapeutics Ltd. ("Arana" or "the Company") is a biotechnology company developing next-generation antibody therapeutics to treat inflammatory diseases and cancer. Arana's business is divided into two sectors: (1) protein engineering technologies; and (2) therapeutics development. The Company's technology platform includes its Superhumanisation(TM), Synhumanisation(R), and EvoGene(TM) proprietary processes. Application of these technologies can transform lead proteins, including antibodies, into safe, potent therapeutic candidates. The resulting products may be less immunogenic (less likely to cause side effects) yet retain the crucial binding properties of the starting antibody.

At present, the Company licenses its protein engineering platform to CSL Ltd. (CSL-ASX), GlaxoSmithKline plc (GSK-NYSE), Aveo Pharmaceuticals, Inc., and Vegenics Ltd. Additionally, Arana can use its technologies to decrease the timeline and minimize the financial risks of its therapeutic antibody development. The Company does this by further enhancing already validated targets that would otherwise be excluded from development due to existing competitor patents.

Arana's product pipeline consists of eight candidates targeting inflammatory diseases as well as bone, lung, and colorectal cancer, melanoma, leukemia, and solid tumors. ART621, the Company's most advanced candidate, is a Tumor Necrosis Factor alpha (TNF alpha)-blocker for rheumatoid arthritis (RA), psoriasis, and Crohn's disease. In March 2008, the Company commenced Phase II clinical trials of ART621 in psoriasis patients. Within Arana's Cancer Franchise, the lead product candidate is ART010, an engineered version of a naturally occurring protein being developed for treating cancer related to bone disease and osteoporosis. Arana expects to begin manufacturing ART010 in 2008 and could enter Phase I trials in late 2009. Arana has headquarters in Sydney, Australia, with facilities in Melbourne, Australia, and San Francisco, California.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
2. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
3. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. Researchers outline structure of largest nonvirus particle ever crystallized
6. 3-D photonic crystals will revolutionize telecommunications
7. Recombinant Human Renin - Crystallographic Grade
8. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
9. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):